Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
Leiomyosarcoma
DRUG: Trabectedin
Progression free survival, Progression free survival up to disease progression or death from any cause, 12 months
Overall Response, Best overall response (BOR) and duration of response (DOR) by RECIST v1.1 via CT scan or MRI, 6 weeks|Adverse Event, Incidence of treatment-related adverse events, 12 months
This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.

A total of 80 patients will receive trabectedin 0.5 mg/m2 as 24 hour continuous intravenous infusion (CIV) on D1 and D8, gemcitabine 200 mg/m2 i.v. on D1 and D8, and dacarbazine 200 mg/m2 i.v. on D1 and D8 (see product information; www.accessdata.fda.gov). Treatment cycles are given every 3 weeks. Patients in this study may continue treatment until significant disease progression or unacceptable toxicity occurs up to one year of therapy. Patients who withdraw or do not complete the first 2 treatment cycles and first follow up CT scan/MRI will be replaced.